Thermo Fisher Scientific
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer.
Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them.
Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
Stock Symbol: TMO
1625 articles about Thermo Fisher Scientific
-
In addition to promoting their brands, companies say their funding initiatives give them access to the expertise of top researchers and contribute to society. -
Thermo Fisher Scientific to Present at BofA Securities 2023 Healthcare Conference on May 10th, 2023
5/2/2023
Thermo Fisher Scientific Inc. announced that Marc N. Casper, chairman, president and chief executive officer, will present at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 11:00 a.m. (EDT).
-
Thermo Fisher Scientific Reports First Quarter 2023 Results
4/26/2023
Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the first quarter ended April 1, 2023.
-
Choose your raw materials wisely -
Devyser enters agreement with Thermo Fisher Scientific for commercialization of Devyser's post-transplant NGS products
4/24/2023
Devyser Diagnostics AB announced that the company has signed an exclusive collaboration and distribution agreement with Thermo Fisher Scientific.
-
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare
4/18/2023
OpGen, Inc. announced that the Company has entered into a non-exclusive distribution agreement with Fisher Healthcare, a part of Thermo Fisher Scientific.
-
Thermo Fisher Scientific Announces Oncomine Clinical Research Grant Awardees and Opens Spring 2023 Submissions
4/17/2023
In support of global initiatives to advance molecular profiling in oncology, Thermo Fisher Scientific announced the latest recipients of the Oncomine Clinical Research Grant and the opening of its submissions for Spring 2023.
-
Thermo Fisher Scientific to Host Investor Day - April 10, 2023
4/10/2023
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will host its 2023 Investor Day on Wednesday, May 24, starting at 9:00 a.m. (ET)in New York City.
-
Thermo Fisher Scientific Expansion in France Boosts Capabilities from Development to Commercial Manufacturing
4/6/2023
Thermo Fisher Scientific, the world leader in serving science, is adding early development work for oral solid dose therapies to its Bourgoin, France site, enabling that location to address customers’ workflow from early drug development through commercial manufacturing and underscoring the company’s commitment to helping clients get medicines to patients sooner.
-
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 26, 2023
4/4/2023
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2023 before the market opens on Wednesday, April 26, 2023, and will hold a conference call on the same day at 8:30 a.m. EST.
-
Thermo Fisher Scientific and Arsenal Biosciences Collaborate to Support Clinical Manufacturing of Autologous T-Cell Therapies
3/29/2023
Thermo Fisher Scientific today announced an update to our strategic collaboration to further the development of manufacturing processes for new cancer treatments.
-
Thermo Fisher Scientific Opens Cell Therapy Facility at University of California, San Francisco, to Accelerate Development of Breakthrough Therapies
3/27/2023
Thermo Fisher Scientific Inc. and the University of California, San Francisco, will accelerate advanced cell therapies for difficult to treat conditions, including cancer, rare diseases, and other illnesses, from a newly opened cGMP manufacturing facility adjacent to UCSF Medical Center’s Mission Bay campus.
-
Stevanato Group Collaborates with Thermo Fisher Scientific to Bring its Innovative On-Body Delivery System Platform to Market
3/21/2023
Stevanato Group S.p.A. announced its collaboration with Thermo Fisher Scientific, the world leader in serving science, to bring to the market a fully integrated on-body delivery system platform for subcutaneous administration.
-
Thermo Fisher Scientific to Present at Cowen 43rd Annual Healthcare Conference on March 6, 2023
2/28/2023
Thermo Fisher Scientific Inc. will present at the Cowen Healthcare Conference on Monday, March 6, 2023 at 9:10 a.m. (EST).
-
Thermo Fisher Scientific Increases Quarterly Dividend - February 22, 2023
2/22/2023
Thermo Fisher Scientific Inc., the world leader in serving science, announced that its Board of Directors has authorized a quarterly cash dividend of $0.35 per common share payable on April 14, 2023, to stockholders of record as of March 15, 2023.
-
Thermo Fisher Scientific Selected to Support National Institute of Health’s Blueprint MedTech program
2/21/2023
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been awarded a five-year contract to provide regulatory affairs support and related services for the Blueprint MedTech (BPMT) program, a new multi-institute/center initiative at the National Institutes of Health (NIH) supporting development of translational neurological devices.
-
Thermo Fisher Scientific Launches TrueMark STI Select Panel
2/8/2023
Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems TrueMark STI Select Panel, a polymerase chain reaction (PCR) research use only test designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium in one test, as well as RNase P, included as a human internal control.
-
Elektrofi Announces Collaboration with Thermo Fisher Scientific to Strengthen Manufacturing Capabilities for Future Clinical Trials
2/7/2023
Elektrofi, a biotechnology company focused on drug formulation and delivery innovations, announced a strategic contract manufacturing agreement with Thermo Fisher Scientific to support clinical manufacture of Elektrofi’s breakthrough ultra-high concentration subcutaneous products.
-
Thermo Fisher Scientific to Power All Current U.S. Sites With 100 Percent Renewable Electricity
2/2/2023
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it will power all of the company’s current U.S. sites with 100 percent renewable electricity by 2026.
-
Bronwyn Brophy is appointed new CEO of Vitrolife AB (publ)
2/1/2023
Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson.